RHB-103 is a proprietary oral fast dissolving thin film formulation of a leading migraine drug. RHB-103 is being co-developed with Montreal-based IntelGenx [OTCBB: IGXT] following the August 2010 RedHill-IntelGenx co-development agreement. RHB-103 will be indicated for the treatment of migraine. A clinical PK study was conducted and RedHill and IntelGenx are currently executing their joint development plan.
Latest News
-
February 15th, 2012
RedHill Biopharma’s RHB-102 (prevention of nausea and vomiting) advanced clinical trial has began -
February 13th, 2012
RedHill Biopharma obtains FDA IND for advanced clinical trial with RHB-102 (Prevention of Nausea and Vomiting) -
February 7th, 2012
RedHill Biopharma obtains a CTA approval from Health Canada to commence an advanced trial with RHB-102 (prevention of nausea & vomiting) -
February 2nd, 2012
Mr. Gilead Raday’s interview on Israel21c, regarding RHB-102 (prevention of nausea & vomiting in cancer patients) -
January 2nd, 2012
IntelGenx, RedHill’s Development Partner in RHB-103 (Migraine) Announces Health Canada Approval for Pivotal Trial
See More News